India's generic pharmacy chain slashes heart medication costs by 90%

Heart disease remains India's biggest killer, accounting for 28.1% of all deaths. With over half a billion people affected by cardiac conditions, the cost of long-term medication adds to the financial strain on families. Now, a pharmacy chain is working to make essential treatments more affordable through quality-assured generic medicines. Medkart, a generic-first pharmacy chain, focuses on reducing the cost of heart medications. The company offers statins, beta-blockers, antiplatelets, and antihypertensives at prices far lower than branded alternatives. For example, a 20mg dose of atorvastatin—a common cholesterol drug—costs five times more in its branded form than as a generic.

To ensure trust in generics, Medkart uses the *Assured* system, verifying quality and compliance. Pharmacists also educate patients on the safety and effectiveness of these alternatives. A comparison tool on their platform helps users see the differences between branded and generic versions of the same medicine. The shift towards generics is already showing impact. In Gujarat, cardiac drug sales rose by 13% in January 2026, outpacing the overall pharmaceutical market's 8% growth. Strong regulatory standards, including WHO-GMP and FDA compliance, have supported this trend. Medkart claims its approach helps patients save up to 90% on repeat prescriptions.

As heart disease continues to affect millions, affordable medication remains critical. Medkart's model combines cost savings with quality checks, making essential treatments more accessible. The rise in generic drug sales suggests growing acceptance of these alternatives across India.